An Investigational Immuno-therapy Study of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma

Official Title

An Open-Label, Randomized Phase 3 Trial of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma- CheckMate 602: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 602


The purpose of this study is to evaluate the safety and effectiveness of several combination therapies for Multiple Myeloma. Upon entry into the study, patients will be randomized (assigned by chance) to receive either: Group 1: nivolumab, pomalidomide and dexamethasone OR Group 2: pomalidomide and dexamethasone OR Group 3: nivolumab, elotuzumab, pomalidomide and dexamethasone There is an equal chance to be assigned to either Group 1 or Group 2. There is a lesser chance you will be assigned to Group 3. If you are assigned to receive pomalidomide and dexamethasone only (Group 2) and your disease worsens, you may be eligible to switch to treatment Group 3.

Trial Description

Primary Outcome:

  • Objective response rate (ORR) by Independent Review Committee (IRC)
  • Progression free survival (PFS) by IRC
Secondary Outcome:
  • Time to objective response (TTR)
  • Duration of objective response (DOR)
  • Investigator-assessed PFS
  • Investigator-assessed ORR

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society